- is an amalgamation of Medical and basic sciences, and is comprehensively written, revised, and updated to meet the curriculum requirements of Medical, Pharmacy, Dental, Veterinary, Biotechnology, Agriculture, Life sciences, and others studying Biochemistry as one of the subjects. - is written in a lucid style with the subject being presented as an engaging story, growing from elementary information to the most recent advances, and with theoretical discussions being supplemented with illustrations, tables, Medical concepts, clinical correlates, and case studies for easy understanding of Biochemistry. - has each chapter beginning with a four-line verse followed by the text with clinical correlates, a summary, and self-assessment exercises. the lively illustrations and text with appropriate headings and sub-headings in bold type faces facilitate reading path clarity and quick recall. All this will help the students to master the subject and boldly face the examinations. - describes a variety of case studies with Medical correlations. the case studies are listed at the end of relevant chapters for immediate reference, quick review, and better understanding of Biochemistry. - contains the basics (Bioorganic and Biophysical Chemistry, Tools of Biochemistry, Immunology, and Genetics) for beginners to learn easily Biochemistry, origins of biochemical words, confusables in Biochemistry, principles of Practical Biochemistry, and clinical Biochemistry Laboratory. - has medically/clinically oriented Biochemistry with inputs from M.D. (Biochemistry) and M.D. (General Medicine) Professors. Satisfies the new MCI/NMC curriculum with a relevant competency map, specifically giving information on competency codes with chapters and pages. - is thoroughly revised and reorganized with special focus on medical concepts/clinical correlates, case studies and current topics such as Diabetes, Cancer, Free Radicals and Antioxidants, COVID-19, etc.

This volume in the Blue Books of Neurology series provides you with rapid access to practical, clinical guidance on the diagnosis and treatment of all forms of dementia, including Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and many others. Organized by the most common neurodegenerative diseases, it reflects new insights regarding commonalities among the neurodegenerative diseases, and clusters them according to their dominant molecular pathologic signatures, so you can best treat any dementia you see. Differentiate among various forms of dementia and provide the appropriate management strategy. Correlate neuroimaging with neuropsychological testing to form more accurate diagnoses. Administer the latest approved drugs to improve your patients' brain function. A new two-color design and full-color images throughout helps you access information more easily. New chapters and new authors help you incorporate the latest information and fresh perspectives into your practice.

The Molecular and Cellular Basis of Neurodegenerative Diseases: Underlying Mechanisms presents the pathology, genetics, biochemistry and cell biology of the major human neurodegenerative diseases, including Alzheimer's, Parkinson's, frontotemporal dementia, ALS, Huntington's, and prion diseases. Edited and authored by internationally recognized leaders in the field, the book's chapters explore their pathogenic commonalities and differences, also including discussions of animal models and prospects for therapeutics. Diseases are presented first, with common mechanisms later. Individual chapters discuss each major neurodegenerative disease, integrating this information to offer multiple molecular and cellular mechanisms that diseases may have in common. This book provides readers with a timely update on this rapidly advancing area of investigation, presenting an invaluable resource for researchers in the field. - Covers the spectrum of neurodegenerative diseases and their complex genetic, pathological, biochemical and cellular features - Focuses on leading hypotheses regarding the biochemical and cellular dysfunctions that cause neurodegeneration - Details features, advantages and limitations of animal models, as well as prospects for therapeutic development - Authored by internationally recognized leaders in the field - Includes illustrations that help clarify and consolidate complex concepts

Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of central nervous system (CNS) and other nerve disorders. The scope of the book series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of contemporary molecular targets involved in neurological and CNS disorders. Reviews presented in the series are mainly focused on clinical and therapeutic aspects of novel drugs intended for these targets. Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field of neurology. The sixth volume of this series features reviews that cover the following topics: -Depression, Insomnia and Atypical Antidepressants -Combination Therapy of Hypothermia for Hypoxic Encephalopathy in Neonates -Development of A “Theranostic Nano-Bullet” for Tinnitus -Dexmedetomidine: From Basic Science to Clinical Application of Brain Protection -Protein Misfolding, Aggregation, Amyloid Formation in Neurodegenerative Diseases

Neurodegenerative diseases are severe, rapidly developing, and currently incurable conditions that result in progressive degeneration and the death of neurons. This causes dementia, movement problems, and essentially loss of personal identity. Amyloids attempts to answer the following questions: (1) why do we develop these severe neurodegenerative diseases? (2) what histological and physiological changes are observed upon development and progression of these diseases? and (3) how can we treat amyloid-associated diseases?